Molecular markers that predict response to combined radiotherapy and immunotherapy in patients with lung adenocarcinoma: a bioinformatics analysis

BACKGROUND: Immunotherapy has had a high success rate in treating lung adenocarcinoma (LUAD) for several decades. However, many patients do not benefit from immunotherapy alone. Recent studies revealed that a combination of immunotherapy and radiotherapy (RT) stimulates a good systemic immune respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Lu, Zhou, Haiting, Wu, Cheng, Peng, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643968/
https://www.ncbi.nlm.nih.gov/pubmed/37969379
http://dx.doi.org/10.21037/tcr-23-968

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643968/
https://www.ncbi.nlm.nih.gov/pubmed/37969379
http://dx.doi.org/10.21037/tcr-23-968

Ejemplares similares